APO Research
Talk to an analyst

APO RESEARCH · REPORT

Circulating Tumor Cell(CTC)Detection

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Circulating Tumor Cell(CTC)Detection Market Analysis and Forecast 2026-2032

5 June 2026235 pages

Choose your research edition.

Industry ResearchCirculating Tumor Cell(CTC)Detection Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Circulating Tumor Cell(CTC)Detection Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Circulating Tumor Cell(CTC)Detection Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032180 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Circulating Tumor Cell(CTC)Detection Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Circulating Tumor Cell(CTC)Detection Market Analysis and Forecast 2026-2032235 pages · $4,950 USD

Market perspective

The global Circulating Tumor Cell(CTC)Detection market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Circulating Tumor Cell(CTC)Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Circulating Tumor Cell(CTC)Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Circulating Tumor Cell(CTC)Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Circulating Tumor Cell(CTC)Detection is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Circulating Tumor Cell(CTC)Detection include Rarecyte, ANGLE plc, Biocept Inc., Bio-Rad Laboratories Inc., Fluxion Biosciences Inc., F. Hoffmann-La Roche AG, Sysmex Europe SE and Qiagen, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Circulating Tumor Cell(CTC)Detection, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Circulating Tumor Cell(CTC)Detection, also provides the revenue of main regions and countries. Of the upcoming market potential for Circulating Tumor Cell(CTC)Detection, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Circulating Tumor Cell(CTC)Detection revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Circulating Tumor Cell(CTC)Detection market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Circulating Tumor Cell(CTC)Detection revenue, projected growth trends, production technology, application and end-user industry.

Circulating Tumor Cell(CTC)Detection Segment by Company

Rarecyte

ANGLE plc

Biocept Inc.

Bio-Rad Laboratories Inc.

Fluxion Biosciences Inc.

F. Hoffmann-La Roche AG

Sysmex Europe SE

Qiagen

Circulating Tumor Cell(CTC)Detection Segment by Type

Epithelial Cell Phenotype

Mesenchymal Cell Phenotype

Mixed Epithelial-Mesenchymal Phenotype

Circulating Tumor Cell(CTC)Detection Segment by Application

Cancer Diagnosis

Tumor Dynamic Assessment

Tumor Recurrence Monitoring

Circulating Tumor Cell(CTC)Detection Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Circulating Tumor Cell(CTC)Detection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Circulating Tumor Cell(CTC)Detection and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Circulating Tumor Cell(CTC)Detection.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Circulating Tumor Cell(CTC)Detection in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Circulating Tumor Cell(CTC)Detection company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Circulating Tumor Cell(CTC)Detection revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Circulating Tumor Cell(CTC)Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Epithelial Cell Phenotype Major Player Table 3. Mesenchymal Cell Phenotype Major Player Table 4. Mixed Epithelial-Mesenchymal Phenotype Major Player Table 5. Global Circulating Tumor Cell(CTC)Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 6. Cancer Diagnosis Major Player Table 7. Tumor Dynamic Assessment Major Player Table 8. Tumor Recurrence Monitoring Major Player Table 9. Circulating Tumor Cell(CTC)Detection Industry Trends Table 10. Circulating Tumor Cell(CTC)Detection Industry Drivers Table 11. Circulating Tumor Cell(CTC)Detection Industry Opportunities and Challenges Table 12. Circulating Tumor Cell(CTC)Detection Industry Restraints Table 13. Global Circulating Tumor Cell(CTC)Detection Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Circulating Tumor Cell(CTC)Detection Market Share by Region (2021-2026) Table 16. Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Circulating Tumor Cell(CTC)Detection Market Share by Region (2027-2032) Table 18. Global Circulating Tumor Cell(CTC)Detection Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Players (2021-2026) Table 20. Global Circulating Tumor Cell(CTC)Detection Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Circulating Tumor Cell(CTC)Detection Key Players Headquarters & Area Served Table 22. Global Circulating Tumor Cell(CTC)Detection Players, Product Type & Application Table 23. Global Circulating Tumor Cell(CTC)Detection Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Circulating Tumor Cell(CTC)Detection by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Circulating Tumor Cell(CTC)Detection Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Type (2021-2026) Table 30. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Type (2027-2032) Table 31. Global Circulating Tumor Cell(CTC)Detection Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Application (2021-2026) Table 35. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Application (2027-2032) Table 36. Rarecyte Company Information Table 37. Rarecyte Business Overview Table 38. Rarecyte Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio Table 40. Rarecyte Recent Development Table 41. ANGLE plc Company Information Table 42. ANGLE plc Business Overview Table 43. ANGLE plc Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio Table 45. ANGLE plc Recent Development Table 46. Biocept Inc. Company Information Table 47. Biocept Inc. Business Overview Table 48. Biocept Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 50. Biocept Inc. Recent Development Table 51. Bio-Rad Laboratories Inc. Company Information Table 52. Bio-Rad Laboratories Inc. Business Overview Table 53. Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 55. Bio-Rad Laboratories Inc. Recent Development Table 56. Fluxion Biosciences Inc. Company Information Table 57. Fluxion Biosciences Inc. Business Overview Table 58. Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio Table 60. Fluxion Biosciences Inc. Recent Development Table 61. F. Hoffmann-La Roche AG Company Information Table 62. F. Hoffmann-La Roche AG Business Overview Table 63. F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio Table 65. F. Hoffmann-La Roche AG Recent Development Table 66. Sysmex Europe SE Company Information Table 67. Sysmex Europe SE Business Overview Table 68. Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio Table 70. Sysmex Europe SE Recent Development Table 71. Qiagen Company Information Table 72. Qiagen Business Overview Table 73. Qiagen Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio Table 75. Qiagen Recent Development Table 76. North America Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 77. North America Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 78. North America Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 79. North America Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 80. North America Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 81. North America Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026) & (US$ Million) Table 82. North America Circulating Tumor Cell(CTC)Detection Revenue by Country (US$ Million) & (2027-2032) Table 83. Europe Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 84. Europe Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 85. Europe Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 86. Europe Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 87. Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 88. Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026) & (US$ Million) Table 89. Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (US$ Million) & (2027-2032) Table 90. China Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 91. China Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 92. China Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 93. China Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 94. Asia Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 95. Asia Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 96. Asia Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 97. Asia Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 98. Asia Circulating Tumor Cell(CTC)Detection Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 99. Asia Circulating Tumor Cell(CTC)Detection Revenue by Region (US$ Million) & (2021-2026) Table 100. Asia Circulating Tumor Cell(CTC)Detection Revenue by Region (US$ Million) & (2027-2032) Table 101. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026) & (US$ Million) Table 102. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032) & (US$ Million) Table 103. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026) & (US$ Million) Table 104. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032) & (US$ Million) Table 105. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 106. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026) & (US$ Million) Table 107. SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (US$ Million) & (2027-2032) Table 108. Research Programs/Design for This Report Table 109. Authors List of This Report Table 110. Secondary Sources Table 111. Primary Sources List of Figures Figure 1. Circulating Tumor Cell(CTC)Detection Image Figure 2. Global Circulating Tumor Cell(CTC)Detection Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Circulating Tumor Cell(CTC)Detection Market Size Share 2021 VS 2025 VS 2032 Figure 4. Epithelial Cell Phenotype Image Figure 5. Mesenchymal Cell Phenotype Image Figure 6. Mixed Epithelial-Mesenchymal Phenotype Image Figure 7. Global Circulating Tumor Cell(CTC)Detection Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 8. Global Circulating Tumor Cell(CTC)Detection Market Size Share 2021 VS 2025 VS 2032 Figure 9. Cancer Diagnosis Image Figure 10. Tumor Dynamic Assessment Image Figure 11. Tumor Recurrence Monitoring Image Figure 12. Global Circulating Tumor Cell(CTC)Detection Market Size (US$ Million) & (2021-2032) Figure 13. Global Circulating Tumor Cell(CTC)Detection Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Circulating Tumor Cell(CTC)Detection Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Circulating Tumor Cell(CTC)Detection Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Circulating Tumor Cell(CTC)Detection Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Type (2021-2032) Figure 20. Global Circulating Tumor Cell(CTC)Detection Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Application (2021-2032) Figure 23. North America Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032) Figure 25. North America Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032) Figure 26. North America Circulating Tumor Cell(CTC)Detection Revenue Share by Country (2021-2032) Figure 27. United States Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032) Figure 32. Europe Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032) Figure 33. Europe Circulating Tumor Cell(CTC)Detection Revenue Share by Country (2021-2032) Figure 34. Germany Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032) Figure 44. China Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032) Figure 45. Asia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032) Figure 47. Asia Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032) Figure 48. Asia Circulating Tumor Cell(CTC)Detection Revenue Share by Region (2021-2032) Figure 49. Japan Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032) Figure 57. SAMEA Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032) Figure 58. SAMEA Circulating Tumor Cell(CTC)Detection Revenue Share by Country (2021-2032) Figure 59. Brazil Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Circulating Tumor Cell(CTC)Detection Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Epithelial Cell Phenotype
  • Mesenchymal Cell Phenotype
  • Mixed Epithelial-Mesenchymal Phenotype
Applications
  • Cancer Diagnosis
  • Tumor Dynamic Assessment
  • Tumor Recurrence Monitoring
Companies covered
  • Rarecyte
  • ANGLE plc
  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • Fluxion Biosciences Inc.
  • F. Hoffmann-La Roche AG
  • Sysmex Europe SE
  • Qiagen

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Circulating Tumor Cell(CTC)Detection Market by Type
  3. 1.2.1 Global Circulating Tumor Cell(CTC)Detection Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Epithelial Cell Phenotype
  5. 1.2.3 Mesenchymal Cell Phenotype
  6. 1.2.4 Mixed Epithelial-Mesenchymal Phenotype
  7. 1.3 Circulating Tumor Cell(CTC)Detection Market by Application
  8. 1.3.1 Global Circulating Tumor Cell(CTC)Detection Market Size by Application, 2021 VS 2025 VS 2032
  9. 1.3.2 Cancer Diagnosis
  10. 1.3.3 Tumor Dynamic Assessment
  11. 1.3.4 Tumor Recurrence Monitoring
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Circulating Tumor Cell(CTC)Detection Market Dynamics
  1. 2.1 Circulating Tumor Cell(CTC)Detection Industry Trends
  2. 2.2 Circulating Tumor Cell(CTC)Detection Industry Drivers
  3. 2.3 Circulating Tumor Cell(CTC)Detection Industry Opportunities and Challenges
  4. 2.4 Circulating Tumor Cell(CTC)Detection Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Circulating Tumor Cell(CTC)Detection Market Perspective (2021-2032)
  2. 3.2 Global Circulating Tumor Cell(CTC)Detection Growth Trends by Region
  3. 3.2.1 Global Circulating Tumor Cell(CTC)Detection Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2021-2026)
  5. 3.2.3 Global Circulating Tumor Cell(CTC)Detection Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Circulating Tumor Cell(CTC)Detection Revenue by Players
  2. 4.1.1 Global Circulating Tumor Cell(CTC)Detection Revenue by Players (2021-2026)
  3. 4.1.2 Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Circulating Tumor Cell(CTC)Detection Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Circulating Tumor Cell(CTC)Detection Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Circulating Tumor Cell(CTC)Detection Key Players Headquarters & Area Served
  7. 4.4 Global Circulating Tumor Cell(CTC)Detection Players, Product Type & Application
  8. 4.5 Global Circulating Tumor Cell(CTC)Detection Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Circulating Tumor Cell(CTC)Detection Market CR5 and HHI
  11. 4.6.3 2025 Circulating Tumor Cell(CTC)Detection Tier 1, Tier 2, and Tier 3
5 Circulating Tumor Cell(CTC)Detection Market Size by Type
  1. 5.1 Global Circulating Tumor Cell(CTC)Detection Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 5.3 Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Type (2021-2032)
6 Circulating Tumor Cell(CTC)Detection Market Size by Application
  1. 6.1 Global Circulating Tumor Cell(CTC)Detection Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  3. 6.3 Global Circulating Tumor Cell(CTC)Detection Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Rarecyte
  2. 7.1.1 Rarecyte Company Information
  3. 7.1.2 Rarecyte Business Overview
  4. 7.1.3 Rarecyte Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Rarecyte Circulating Tumor Cell(CTC)Detection Product Portfolio
  6. 7.1.5 Rarecyte Recent Developments
  7. 7.2 ANGLE plc
  8. 7.2.1 ANGLE plc Company Information
  9. 7.2.2 ANGLE plc Business Overview
  10. 7.2.3 ANGLE plc Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  11. 7.2.4 ANGLE plc Circulating Tumor Cell(CTC)Detection Product Portfolio
  12. 7.2.5 ANGLE plc Recent Developments
  13. 7.3 Biocept Inc.
  14. 7.3.1 Biocept Inc. Company Information
  15. 7.3.2 Biocept Inc. Business Overview
  16. 7.3.3 Biocept Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Biocept Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  18. 7.3.5 Biocept Inc. Recent Developments
  19. 7.4 Bio-Rad Laboratories Inc.
  20. 7.4.1 Bio-Rad Laboratories Inc. Company Information
  21. 7.4.2 Bio-Rad Laboratories Inc. Business Overview
  22. 7.4.3 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Bio-Rad Laboratories Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  24. 7.4.5 Bio-Rad Laboratories Inc. Recent Developments
  25. 7.5 Fluxion Biosciences Inc.
  26. 7.5.1 Fluxion Biosciences Inc. Company Information
  27. 7.5.2 Fluxion Biosciences Inc. Business Overview
  28. 7.5.3 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Fluxion Biosciences Inc. Circulating Tumor Cell(CTC)Detection Product Portfolio
  30. 7.5.5 Fluxion Biosciences Inc. Recent Developments
  31. 7.6 F. Hoffmann-La Roche AG
  32. 7.6.1 F. Hoffmann-La Roche AG Company Information
  33. 7.6.2 F. Hoffmann-La Roche AG Business Overview
  34. 7.6.3 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  35. 7.6.4 F. Hoffmann-La Roche AG Circulating Tumor Cell(CTC)Detection Product Portfolio
  36. 7.6.5 F. Hoffmann-La Roche AG Recent Developments
  37. 7.7 Sysmex Europe SE
  38. 7.7.1 Sysmex Europe SE Company Information
  39. 7.7.2 Sysmex Europe SE Business Overview
  40. 7.7.3 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Sysmex Europe SE Circulating Tumor Cell(CTC)Detection Product Portfolio
  42. 7.7.5 Sysmex Europe SE Recent Developments
  43. 7.8 Qiagen
  44. 7.8.1 Qiagen Company Information
  45. 7.8.2 Qiagen Business Overview
  46. 7.8.3 Qiagen Circulating Tumor Cell(CTC)Detection Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Qiagen Circulating Tumor Cell(CTC)Detection Product Portfolio
  48. 7.8.5 Qiagen Recent Developments
8 North America
  1. 8.1 North America Circulating Tumor Cell(CTC)Detection Revenue (2021-2032)
  2. 8.2 North America Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 8.2.1 North America Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026)
  4. 8.2.2 North America Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032)
  5. 8.3 North America Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032)
  6. 8.4 North America Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  7. 8.4.1 North America Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026)
  8. 8.4.2 North America Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032)
  9. 8.5 North America Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032)
  10. 8.6 North America Circulating Tumor Cell(CTC)Detection Revenue by Country
  11. 8.6.1 North America Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026)
  13. 8.6.3 North America Circulating Tumor Cell(CTC)Detection Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Circulating Tumor Cell(CTC)Detection Revenue (2021-2032)
  2. 9.2 Europe Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 9.2.1 Europe Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026)
  4. 9.2.2 Europe Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032)
  5. 9.3 Europe Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032)
  6. 9.4 Europe Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  7. 9.4.1 Europe Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026)
  8. 9.4.2 Europe Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032)
  9. 9.5 Europe Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032)
  10. 9.6 Europe Circulating Tumor Cell(CTC)Detection Revenue by Country
  11. 9.6.1 Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026)
  13. 9.6.3 Europe Circulating Tumor Cell(CTC)Detection Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Circulating Tumor Cell(CTC)Detection Revenue (2021-2032)
  2. 10.2 China Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 10.2.1 China Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026)
  4. 10.2.2 China Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032)
  5. 10.3 China Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032)
  6. 10.4 China Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  7. 10.4.1 China Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026)
  8. 10.4.2 China Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032)
  9. 10.5 China Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Circulating Tumor Cell(CTC)Detection Revenue (2021-2032)
  2. 11.2 Asia Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 11.2.1 Asia Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026)
  4. 11.2.2 Asia Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032)
  5. 11.3 Asia Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032)
  6. 11.4 Asia Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  7. 11.4.1 Asia Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026)
  8. 11.4.2 Asia Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032)
  9. 11.5 Asia Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032)
  10. 11.6 Asia Circulating Tumor Cell(CTC)Detection Revenue by Country
  11. 11.6.1 Asia Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026)
  13. 11.6.3 Asia Circulating Tumor Cell(CTC)Detection Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Circulating Tumor Cell(CTC)Detection Revenue (2021-2032)
  2. 12.2 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Type (2027-2032)
  5. 12.3 SAMEA Circulating Tumor Cell(CTC)Detection Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Application (2027-2032)
  9. 12.5 SAMEA Circulating Tumor Cell(CTC)Detection Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country
  11. 12.6.1 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Circulating Tumor Cell(CTC)Detection Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst